Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 273,000 shares, an increase of 134.9% from the December 31st total of 116,200 shares. Based on an average daily trading volume, of 242,400 shares, the short-interest ratio is currently 1.1 days. Approximately 6.3% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

VVOS has been the topic of several research analyst reports. Alliance Global Partners decreased their target price on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 19th. Ascendiant Capital Markets reissued a “buy” rating and set a $6.60 price objective on shares of Vivos Therapeutics in a research note on Wednesday, November 20th.

Vivos Therapeutics Trading Down 7.3 %

Shares of NASDAQ:VVOS opened at $3.93 on Friday. The stock has a 50-day simple moving average of $4.48 and a 200-day simple moving average of $3.29. Vivos Therapeutics has a 1 year low of $1.91 and a 1 year high of $7.74.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.